Aurora BioPharma Announces Participation at the Scientific Meeting and Education Day of the Society for Neuro-Oncology
Cambridge, MA -- Aurora BioPharma announces attendance at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology taking place November 16 -19th at the Marriott Marquis in San Francisco.
About the Society for Neuro-Oncology
The Society for Neuro-Oncology is a multidisciplinary organization formed 22 years to promote advances in neuro-oncology through research and education. The Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals. The organization's main focus is central nervous system tumors in children and adults. The highlight of this year's meeting are the 10 Blue Ribbon Panel Recommendations related to the 'Cancer Moonshot' program. A member of the Blue Ribbon Panel, Dr. WK Alfred Yung, will present an introduction to the Moonshot program and three prominent keynote speakers will offer presentations related to the specific recommendations.
About Aurora BioPharma
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Aurora's CAR T drug AU105 completed Phase I/IIa clinical trial in 16 Glioblastoma patients showing safety, tumor killing efficacy, double the median historic overall survival, with 3 patients alive after 5 years. Aurora's CAR T drug AU101 completed a Phase IIa trial in 6 Sarcoma patients, showing safety, tumor-killing and a Complete Response ---cancer free after 5 years. Aurora is planning a pivotal trial of its CAR T Cell therapy in Glioblastoma and Osteosarcoma.
-
Most popular related searches
Related products
Customer comments
No comments were found for Aurora BioPharma Announces Participation at the Scientific Meeting and Education Day of the Society for Neuro-Oncology. Be the first to comment!